Stoke Therapeutics STOK Q2 2026: EPS Miss as Pre-Launch Spending Surges
As seen on the 24/7 Wall St. homepage on August 3, 2026.
Roughly $420 million in liquidity funds the rolling NDA starting Q1 2027 and a 2028 launch, with Phase 3 EMPEROR fully enrolled at 162 patients and zero discontinuations. R&D nearly doubled to $49.5 million, and the loss per share missed expectations as pre-commercial spending accelerated.
Continue ReadingShow less
Stoke Therapeutics reported a Q2 2026 loss of $0.93 per share, coming in about 19% worse than the consensus estimate of $0.78. The shortfall was driven by a near-doubling of R&D spending to $49.5 million as the company accelerates pre-commercial activity ahead of a planned rolling NDA submission starting in Q1 2027 and a targeted 2028 product launch. Revenue, at $9.3 million, beat expectations of $5.1 million by more than 83%.
The clinical picture behind that spending looks solid. Phase 3 EMPEROR trial enrollment is complete at 162 patients, and the company has reported zero discontinuations — a detail that will matter to investors watching for safety signals as the regulatory timeline draws closer. Stoke enters this stretch with roughly $420 million in liquidity, which management points to as sufficient runway to fund both the NDA process and the eventual launch.
Sponsored
Are You Ready To Retire, Or Years Behind?
Most Americans suspect they're behind on retirement and never find out. Advisor.com's free matching tool pairs you in about three minutes with a vetted fiduciary advisor who can help you with investing, taxes, retirement, estate planning, and more. No minimums. No sales call. Find out where you stand.
Looking back over recent quarters, the EPS trajectory reflects the deliberate ramp-up in spending: losses widened from $0.79 in Q1 2026 to $0.93 here, continuing a trend that began after a one-time gain inflated Q1 2025 results to $1.90. The key milestones to watch now are the rolling NDA initiation in early 2027 and any interim data readouts from EMPEROR.
Mentioned: STOK